Biotechnology company Iolyx Therapeutics has entered a strategic development and commercialisation agreement with ophthalmic specialty company Laboratoires Théa to advance its retinal pipeline. Under the license and development agreement, Iolyx has granted Théa exclusive worldwide development and commercialisation rights, excluding Asia, to ILYX-002 for the treatment of ocular surface diseases. Iolyx will receive up to $280 million including clinical, regulatory and commercial […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!